Kersh Ellen N, Henning Tara R, Dobard Charles, Heneine Walid, McNicholl Janet M
Division of HIV/ AIDS Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia .
AIDS Res Hum Retroviruses. 2015 Nov;31(11):1166-9. doi: 10.1089/AID.2014.0373. Epub 2015 Aug 6.
Vaginal SHIVSF162P3 acquisition in pigtail macaques (Macaca nemestrina) is dependent on time point during the menstrual cycle. Susceptibility is higher around menstruation and lower at ovulation in mid cycle. This complicates the design of repeat low-dose (RLD) SHIV exposure studies because virus challenges given during low susceptibility periods have lower chances to infect. To account for fluctuating susceptibility, we analyzed menstrual cycles rather than exposures until infection following virus challenges. We first reanalyzed infection data of 41 macaques receiving placebo or no treatment during once (n=18) or twice (n=23) weekly virus exposures. The same number of cycles was required for infection with either challenge frequency, while it took a median four or six challenges for once or twice weekly exposures, respectively. More virus challenges to infection likely reflect frequent unsuccessful exposures in frequently exposed animals. When reanalyzing two previously reported biomedical HIV intervention studies, we found 1% tenofovir gel was 74% or 86% efficacious based on cycles or exposures (p=0.019 or p=0.003, respectively, Fisher's exact test), while 1% raltegravir gel was 84% or 89 % efficacious, respectively (p=0.047 or p=0.031). Evaluating the number of menstrual cycles rather than exposures until infection can account for varying susceptibility during the menstrual cycle. Our observations have implications for future study designs such as planning the frequency of virus exposures. Menstrual cycle analysis may also avoid potential overestimation of efficacy against vaginal challenges during low susceptibility periods in the cycle that are unlikely to cause infection.
猪尾猕猴(食蟹猴)阴道感染猿猴 - 人免疫缺陷病毒嵌合体SF162P3(SHIVSF162P3)取决于月经周期中的时间点。月经前后易感性较高,而在月经周期中期排卵时易感性较低。这使得重复低剂量(RLD)SHIV暴露研究的设计变得复杂,因为在低易感性时期进行病毒攻击时感染的机会较低。为了考虑易感性的波动,我们分析了月经周期,而不是病毒攻击后直至感染的暴露次数。我们首先重新分析了41只猕猴的感染数据,这些猕猴在每周一次(n = 18)或两次(n = 23)的病毒暴露期间接受安慰剂或未接受治疗。无论攻击频率如何,感染所需的周期数相同,而每周一次或两次暴露分别需要中位数为4次或6次攻击。更多的病毒攻击才导致感染可能反映了频繁暴露的动物中频繁的未成功暴露。在重新分析两项先前报道的生物医学HIV干预研究时,我们发现基于周期或暴露次数,1%的替诺福韦凝胶有效率分别为74%或86%(Fisher精确检验,p分别为0.019或0.003),而1%的拉替拉韦凝胶有效率分别为84%或89%(p分别为0.047或0.031)。评估月经周期数而不是直至感染的暴露次数可以解释月经周期中不同的易感性。我们的观察结果对未来的研究设计有影响,例如规划病毒暴露的频率。月经周期分析还可以避免在周期中低易感性时期对阴道攻击疗效的潜在高估,因为这些时期不太可能引起感染。